Navigation Links
Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Date:2/8/2008

MALVERN, Pa., Feb. 8 /PRNewswire/ -- Safety of patients treated with Myobloc(R) (Botulinum Toxin Type B) Injectable Solution has always been of primary importance for Solstice Neurosciences, Inc. ("Solstice"). We support education and training of physicians in a number of ways regarding the proper use of this product as outlined in the prescribing information.

We maintain a rigorous and routine process for monitoring and reporting any adverse events to regulatory authorities in compliance with all applicable regulations.

Manufacturers of botulinum toxin products have recently submitted safety information to the FDA. In its review of this information and other available data, the Agency's posting of this Early Communication "does not mean that FDA has concluded there is a causal relationship between the drug products and the emerging safety issue."

Solstice supports the FDA review of botulinum toxins and remains committed to providing FDA with any additional information needed.

About MYOBLOC

MYOBLOC was the first drug approved in the US to reduce the severity of abnormal head position and the neck pain associated with cervical dystonia. When injected into an affected muscle, botulinum toxin type B inhibits the release of the neurotransmitter, acetylcholine, at the motor nerve terminals to allow it to relax.

Regulatory approvals in the US, EU and Canada were based on the results from randomized, multi-center, double-blind, placebo-controlled studies in adult patients with cervical dystonia.

MYOBLOC is supplied as a ready-to-use, injectable solution in three single-dose vial sizes of 0.5 mL (2,500 U), 1.0 mL (5,000 U), and 2.0 mL (10,000 U). Unopened vials of MYOBLOC have demonstrated stability when stored at 2-8 degrees Celsius, and are approved for a 36-month shelf life in the EU, and a 48-month shelf-life in the US and Canada.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC, represents the only botulinum toxin type B currently available to physicians and patients worldwide. MYOBLOC is sold in the United States and is approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com

Myobloc(R) is a registered trademark of Solstice Neurosciences, Inc.


'/>"/>
SOURCE Solstice Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
2. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
7. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
8. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
9. CCPM Issues Statement on FDAs GIVE Initiative
10. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
11. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... This June ... Tampa, Florida. As an exclusive sales and service provider of the ALPINION line, ... 2016 is the premier conference for healthcare technology management. The event draws more than ...
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS Neurosciences ... its first three targets, it has identified a fourth in a series of ... the development and progression of Alzheimer’s disease (AD). , “This discovery ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... growth, has leveraged recent innovations in biotechnology to help treat hormonal and stress ... hair loss, Nutrafol® has captured the hearts of key opinion leaders in the ...
Breaking Biology Technology:
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
(Date:3/3/2016)... , March 3, 2016  2016FLEX, organized by ... week highlighting advancements in flexible, hybrid and printed ... setting attendance - have gathered for short courses, ... field of electronics. The Flex Conference celebrates its ... for companies, R&D organizations, and universities contributing to ...
(Date:3/2/2016)... March 2, 2016 ... addition of the  "Global Biometrics Market in ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , Global biometrics ... at a CAGR of around 27%   ... has announced the addition of the  "Global ...
Breaking Biology News(10 mins):